Journal article · 2025 · Open access
Overall survival as a safety guardrail in cancer drug trials
Journal of Cancer Policy, 46, 100666 · Published 9 November 2025 · DOI 10.1016/j.jcpo.2025.100666
In brief
“Overall survival as a safety guardrail in cancer drug trials” is a 2025 journal article by Rashidul Alam Mahumud, published in Journal of Cancer Policy. OpenAlex counts 0 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Cancer Policy.
- Citations
- 0
- References
- 7
- Authors
- 1
Abstract
Surrogate endpoints have accelerated access to oncology drugs but often leave uncertainty about net patient benefit. We propose a pragmatic framework that recentres overall survival (OS) as both the definitive patient-centred efficacy endpoint and a safety guardrail capable of detecting net harm that intermediate measures may miss. The framework comprises four pillars. First, designing for harm exclusion: protocols should prespecify a clinically meaningful OS harm margin, power event-driven follow-up to exclude or detect that margin with precision, and mandate independent data monitoring committee oversight. Analyses should match explicit estimands and pair hazard ratios with restricted mean survival time to accommodate non-proportional hazards. Second, handling crossover and post-progression therapy: when crossover is ethical or unavoidable, trials should adopt treatment-policy estimands for the primary question and prespecified causal sensitivity analyses. Protocols must map access to guideline-concordant post-progression care, record uptake and timing, and distinguish biological dilution from health-system scarcity. Third, using surrogates with discipline: when OS cannot feasibly be primary, sponsors should submit a disease-specific surrogate dossier summarising trial- and patient-level validation and quantifying expected translation to OS, while continuing to collect OS and assess it against the prespecified harm boundary. Fourth, preventing missingness-driven bias: continue outcome collection after treatment discontinuation, set triggers for asymmetric loss to follow-up, and perform structured tipping-point analyses. We recommend a regulatory traffic-light aligned to OS maturity, green (traditional approval), amber (time-limited with confirmatory obligations), red (standards unmet), and conditioning economic conclusions (QALYs, net monetary benefit) on OS harm exclusion. Operationalising OS as a safety guardrail protects patients and strengthens the credibility and value of cancer trials.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Mahumud, R. A. (2025). Overall survival as a safety guardrail in cancer drug trials. Journal of Cancer Policy, 46, 100666. https://doi.org/10.1016/j.jcpo.2025.100666
MLA 9
Mahumud, Rashidul Alam. “Overall survival as a safety guardrail in cancer drug trials.” Journal of Cancer Policy, vol. 46, 2025, p. 100666. https://doi.org/10.1016/j.jcpo.2025.100666.
Chicago
Mahumud, Rashidul Alam. 2025. “Overall survival as a safety guardrail in cancer drug trials.” Journal of Cancer Policy 46: 100666. https://doi.org/10.1016/j.jcpo.2025.100666.
Harvard
Mahumud, R. A. (2025) ‘Overall survival as a safety guardrail in cancer drug trials’, Journal of Cancer Policy, 46, p. 100666. doi:10.1016/j.jcpo.2025.100666.
IEEE
R. A. Mahumud, “Overall survival as a safety guardrail in cancer drug trials,” Journal of Cancer Policy, vol. 46, p. 100666, 2025, doi: 10.1016/j.jcpo.2025.100666.
BibTeX
@article{mahumud2025overall,
title = {{Overall survival as a safety guardrail in cancer drug trials}},
author = {Mahumud, Rashidul Alam},
journal = {Journal of Cancer Policy},
year = {2025},
volume = {46},
pages = {100666},
doi = {10.1016/j.jcpo.2025.100666},
url = {https://doi.org/10.1016/j.jcpo.2025.100666}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- overall survival
- surrogate endpoints
- cancer drug trials
- data monitoring committees
- restricted mean survival time
- estimands
- treatment policy estimand
- crossover
Work with this paper
Most-cited papers in Mathematics
- Random ForestsLeo Breiman · Machine Learning · 2001 · 142,830 citations
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingYoav Benjamini, Yosef Hochberg · Journal of the Royal Statistical Society Series B (Statistical Methodology) · 1995 · 113,923 citations
- Fitting Linear Mixed-Effects Models Using lme4Douglas M. Bates, Martin Maechler, Benjamin M. Bolker and 1 more · Journal of Statistical Software · 2015 · 100,328 citations
- The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.Reuben M. Baron, David A. Kenny · Journal of Personality and Social Psychology · 1986 · 95,866 citations
- Using multivariate statisticsBarbara Gerson Tabachnick, Linda S. Fidell · 1983 · 79,867 citations
Questions about this paper
How do I cite this paper in APA style?
Mahumud, R. A. (2025). Overall survival as a safety guardrail in cancer drug trials. Journal of Cancer Policy, 46, 100666. https://doi.org/10.1016/j.jcpo.2025.100666
How many times has this paper been cited?
0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Cancer Policy: sign in and open the full text from this page.
Who wrote this paper?
Rashidul Alam Mahumud.
What is the DOI of this paper?
10.1016/j.jcpo.2025.100666, permanently at https://doi.org/10.1016/j.jcpo.2025.100666. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.